Home » Amgen’s XGEVA Granted Marketing Authorization In European Union
Amgen’s XGEVA Granted Marketing Authorization In European Union
Amgen said the European Commission has granted marketing authorization for XGEVA for the prevention of skeletal-related events in adults with bone metastases from solid tumors. This approval of XGEVA applies to all 27 EU member states.
RTTNews
RTTNews
Upcoming Events
-
07May
-
14May
-
30May